
Affimed prices public offering to finance NK cell trials
German Affimed N.V. has priced its previously announced public offering of 22,500,000 common shares at a $4.00 per common share. A 30-day...

Cannabis players Canify AS and Bavaria Weed merge to form Canify AG
The merger combines Canify AS’s expertise in the production of pharna-grade medical cannabis with the market position of Bavaria Weed GmbH, as...

Evotec signs contracts with Almirall and Sernova
Under the alliance Evotec is set to discover novel targets or therapeutics for skin diseases such as atopic dermatitis or basal cell carcinoma....

EMA delays Valneva vaccine approval
The CHMP’s action puts pressure on the French-Austrian vaccine developer, which wanted to market the vaccine from April on as the UK has already...

AXA launches €440 m private equity healthcare strategy
The Strategy focuses specifically on companies in four core areas: medical devices, biopharmaceuticals, vaccines, and diagnostics. The...

Sanofi and IGM Biosciences Inc. in $6.15bn deal
Under the agreement, IGM Biosciences Inc. (Mountain View) will discover IgM antibody agonists against three oncology targets and...

Orphan drug developer Minoryx raises €51m
The Series C round was co-led by Columbus Venture Partners and Caixa Capital Risc, and supported by CDTI Innvierte, Fund+, Ysios Capital and other...